VivoSim Labs (FRA:4OR) Change In Receivables: €-0.01 Mil (TTM As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €9.41
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Change In Receivables?

VivoSim Labs FRA:4OR 39 Change In Receivables is €-0.01 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €9.41. The stock has 4 warning signs investors should review.

VivoSim Labs's change in receivables for the quarter that ended in Dec. 2025 was €-0.00 Mil. It means VivoSim Labs's Accounts Receivable increased by €0.00 Mil from Sep. 2025 to Dec. 2025 .

VivoSim Labs's change in receivables for the fiscal year that ended in Mar. 2025 was €0.00 Mil. It means VivoSim Labs's Accounts Receivable declined by €0.00 Mil from Mar. 2024 to Mar. 2025 .

VivoSim Labs's Accounts Receivable for the quarter that ended in Dec. 2025 was €0.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. VivoSim Labs's Days Sales Outstanding for the three months ended in Dec. 2025 was 116.14.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. VivoSim Labs's liquidation value for the three months ended in Dec. 2025 was €1.53 Mil.

VivoSim Labs  (FRA:4OR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

VivoSim Labs's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.028/0.022*91
=116.14

2. In Ben Graham's calculation of liquidation value, VivoSim Labs's accounts receivable are only considered to be worth 75% of book value:

VivoSim Labs's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3.662-2.151+0.75 * 0.028+0.5 * 0
=1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Change In Receivables Related Terms

VivoSim Labs Change In Receivables Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Change In Receivables Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.00 -0.14 0.11 0.00

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00
FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-0.01 Mil mean?
VivoSim Labs (FRA:4OR) has a Change In Receivables of €-0.01 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for VivoSim Labs and its competitors.
Is VivoSim Labs' Change In Receivables too high?
VivoSim Labs' current Change In Receivables is €-0.01 Mil. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Change In Receivables compare to SLXN and CDT?
VivoSim Labs' Change In Receivables of €-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for VivoSim Labs and its competitors. VivoSim Labs's current Change In Receivables is €-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Change In Receivables of €-0.01 Mil. The stock's GF Value™ is €9.41, compared to a current price of €3.49 — trading 62.9% below its estimated fair value. The current Change In Receivables is €-0.01 Mil. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Change In Receivables is €-0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 62.9% below its estimated GF Value™ of €9.41.

Key valuation signals for FRA:4OR:

  • Change In Receivables: €-0.01 Mil
  • GF Value™: €9.41 vs. price of €3.49 (62.9% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€9.41
GF Value